Summary
Photosensitivity reactions evoked by systemic agents are the result of the effects of the agent combined with subsequent exposure to light. Photosensitivity induced by exogenous parenteral agents accounts for an increasing portion of the total undesirable effects caused by environmental chemicals. The exponential increase in the number of new drugs introduced each year may be one of the factors explaining the increased number of reports describing photosensitivity induced by exogenous agents.
There are many reports of photosensitivity caused by antipsychotic and antidepressant agents. Although the majority of the research was focused on the photosensitising potential of chlorpromazine, other antipsychotics and antidepressants have been shown to cause cutaneous photosensitivity. An extensive drug history must be taken whenever a patient presents with a reaction limited to, or accentuated in, light-exposed areas. It should be remembered that these reactions may present with a wide morphological spectrum ranging from sunburn-like responses to eczematous, lichenoid and even bullous lesions, resembling porphyria cutanea tarda.
In order to properly diagnose photosensitivity to systemic drugs it is important to prove photosensitivity by phototesting and to rule out other causes of systemic photosensitivity such as systemic lupus erythematosus and porphyria cutanea tarda.
Similar content being viewed by others
References
Srebrnik A, Hes J, Brenner S. Adverse cutaneous reactions to psychotropic drugsa. Acta Derm Venereol (Stockh): 1991; Suppl. 158: 3–12
Harth Y. Photosensitivity to systemic agents. In: DeLeo VA, editor. Photosensitivity diseases. Tokyo: Igaku-Shoin Medical Publishers Tokyo: Igaku-Shoin Medical Publishers, 1992: 56–83
Kochevar IE. Phototoxicity mechanisms: chlorpromazine photosensitized damage to DNA and cell membranes. J Invest Dermatol 1981; 77: 59–64
Kochevar IE. Mechanisms of drug photosensitivity. Photochern Photobiol 1987; 45: 891–5
Harber LC, Bickers DR. Photosensitivity diseases. 2nd ed. Philadelphia: BC Decker, 1989; 16–202
Stern RB, Thibodeau LA, Kleinman RA, et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979; 300: 809–13
Baran R, Brun P. Photo-onycholysis induced by the fluoroquinolones pefloxacine and ofloxacine. Dermatologica 1986; 173: 185–8
Jeanmougin M, Morel P, Civatte J. Photo-onycholyse induit par la doxycycline. Ann Dermatol Veneorol 1982; 28: 53–4
Kestel JL. Photo-onycholysis from minocycline. Side effects of minocycline therapy. Cutis 1981; 28: 53–4
Sanders CV, Saenz RE, Lopez M. Splinter hemorrhages and onycholysis: unusual reactions associated with tetracycline hydrochloride therapy. South Med J 1976; 69: 1090–2
Epstein JH. Phototoxicity and photoallergy. In: Pathak MA, editor. Sunlight and man. Tokyo: University of Tokyo Press, 1974; 459–77
Lever W, Schaumberg-Lever G. Histopathology of the skin. Philadelphia: Lippincott, 1990: 286
Abel EA, Farber EM. Photochemotherapy. In: Rook AF, editor. Recent advances in dermatology. Edinburgh: Churchill-Livingstone, 1980: 259–83
Rosenthal I, Ben-Hur E, Prager A, et al. Photochemical reactions of chlorpromazine: chemical and biochemical implications. Photochem Photobiol 1978; 28: 591–4
West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and non photodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23: 689–93
Morison WL, Kochevar IE. Photoallergy. In: Parrish JA, Kripke ML, Morison WL, editors. Photoimmunology. New York: Plenum, 1983
Emmett AE. Diphenhydramine photoallergy. Arch Dermatol 1974; 110: 249–52
Guidici PA, Maguire HC. Experimental photoallergy to systemic drugs. J Invest Dermatol 1985; 85: 207–11
Epstein S. Photoallergy versus phototoxicity. In: Dermatoses due to environmental and physical factors. Springfield: Thomas, 1962: 119–35
Lever W, Schaumberg-Lever G. Histopathology of the skin. Philadelphia: Lippincott, 1990; 107
Schutz, et al. Arch Klin Exp Dermatol 1956; 202: 285
Epstein FH, Brunsting LA, Peterson MC, et al. A study of photosensitivity occurring with chlorpromazine therapy. J Invest Dermatol 1957; 28: 329–38
Ayd JF. The dermatologic and systemic manifestations of chlorpromazine hypersensitivity. J Nerv Ment Dis 1956; 124: 84–7
Calnan CD, Frain-Bell W, Cuthbert JW. Occupational dermatitis from chlorpromazine. Trans St Johns Hosp Dermatol Soc 1962; 48: 49–70
Epstein S. Chlorpromazine photosensitivity. Arch Dermatol 1968; 98: 354–63
Hays GB, Lyle CB, Wheeler CE. Slate-gray color in patients receiving chlorpromazine. Arch Dermatol 1964; 90: 471–6
Hashimoto K, Wiener W, Albert J, et al. An electron microscopi study of chlorpromazine pigmentation. J Invest Dermatol 1966; 47: 296–306
Blois MS. On chlorpromazine binding in vivo. J Invest Dermatol 1965; 45475–481
Palidavskey GP, Hashimoto K, Heller GL, et al. Chlorpromazine induced lupus like disease: case report and review of the literature. J Am Acad Dermatol 1985; 13: 109–15
Flor-Alberti AJ. Chlorpromazine-induced lupus-like illness. Am Fam Physician 1983; 27: 151–2
Hashimoto K, Nizuma K. Skin pathology by light and electron microscopy. New York: Igaku-Shoin Medical Publishers, Inc. 1983: 82
Satanove A, Mclntosh JS. Phototoxic reactions induced by high dosages of chlorpromazine and thioridazine. JAMA 1967; 200: 209–12
Gammon WR, Caro I, Long JC, et al. Secondary cutaneous mucinosis with systemic lupus erythematosus: a case presentation and review of the literature. Arch Dermatol 1978; 114: 432–5
Magnus UA. Dermatological photobiology. Clinical and experimental aspects. Oxford: Blackwell, 1976
Photosensitivity from drugs, perfumes and cosmetics. Med Lett Drugs Ther 1980; 22: 64
Basier RS, Goetz CS. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation [letter]. J Am Acad Dermatol 1985; 12: 577
Basier RSW, Kohnen PW. Localized hemosiderosis as a sequella of acne. Arch Dermatol 1978; 114: 1695–7
Walter-Ryan WG, Kern III EE, Shirriff JR, et al. Persistent photoaggravated cutaneous eruption induced by imipramine. JAMA 1985; 357–8
Hare PJ. ‘Visage Mauve’ (from imipramine?). Br J Dermatol 1970; 83: 420
Torras H, Mascaro Jr JM, Mascaro JM. Photo-onycholysis caused by clorazepate dipotassium. J Am Acad Dermatol 1989; 21: 1304–5
Kanwar AJ, Gupta R, Das Mehta S, et al. Photosensitivity to alprazolam [letter]. Dermatologica 1990; 181: 75
Luton EF, Finchum RN. Photosensitivity reaction to chlordiazepoxide. Arch Dermatol 1965; 91: 362–3
Davis JM. Minor tranquilizers, sedatives and hypnotics. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1985; 1537–53
Hicks JH. ‘Lupus erythematosus-like’ syndrome from chlordiazepoxide. Cutis 1973; 11: 33–8
Bakri A, Van Henegouwen GB, Chanel JL. Involvement of the N4-oxide group in the phototoxicity of chlordiazepoxide in the rat. Photodermatol 1985; 2: 205–12
Epstein JH, Wintroub BU. Photosensitivity due to drugs. Drugs 1985; 30: 42–57
Toback AC, Anders JE. Phototoxicity from systemic agents. In: DeLeo VA, editor. Photosensitivity diseases. Dermatol Clin 1986; 4: 223–30
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harth, Y., Rapoport, M. Photosensitivity Associated with Antipsychotics, Antidepressants and Anxiolytics. Drug-Safety 14, 252–259 (1996). https://doi.org/10.2165/00002018-199614040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199614040-00005